Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...
The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...
The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...
DYNAMIKA V.7 has achieved the British Standards Institute (BSI) surveillance audit certification following a recent SOC II Type I compliance certification LONDON, Jan. 29, 2025 /PRNewswire/ ...
A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus-host disease in patients undergoing stem cell transplantation for blood ...
Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...
A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback